Nabilone
- Generic Name
- Nabilone
- Brand Names
- Cesamet
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36O3
- CAS Number
- 51022-71-0
- Unique Ingredient Identifier
- 2N4O9L084N
- Background
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however...
- Indication
Nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Nabilone can be expected to experience disturbing psychotomimetic re...
- Associated Conditions
- Refractory Chemotherapy-Induced Nausea and Vomiting (CINV)
- Associated Therapies
- -
Cannabinoid Medication for Adults With OCD
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 16
- Registration Number
- NCT02911324
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 78
- Registration Number
- NCT02802540
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Mexico
Safety and Efficacy of Nabilone in Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 38
- Registration Number
- NCT02351882
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 331
- Registration Number
- NCT02115529
- Locations
- 🇨🇦
St Michael's Hospital, Toronto, Ontario, Canada
Nabilone for Cannabis Dependence: A Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT01347762
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Nabilone for the Treatment of Phantom Limb Pain
- Conditions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 50
- Registration Number
- NCT00699634
- Locations
- 🇨🇦
Rehabilitation Hospital, Winnipeg, Manitoba, Canada
Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-05-30
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 50
- Registration Number
- NCT00480181
- Locations
- 🇨🇦
Health Sciences Centre Multiple Sclerosis Clinic, Winnipeg, Manitoba, Canada
A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting
- Conditions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- Veeda Oncology
- Target Recruit Count
- 16
- Registration Number
- NCT00418678
- Locations
- 🇺🇸
Veeda Oncology, Columbus, Ohio, United States
Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2006-10-06
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 16
- Registration Number
- NCT00384410
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia
- Conditions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 32
- Registration Number
- NCT00381199
- Locations
- 🇨🇦
McGill University Health Centre, Pain Centre, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.